All In Biotech

Drug Trial Radar · NCT07926048

A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Phase III, Multicenter, Randomized, Open-Label, Controlled Study of QLS5132 Versus Investigator's Choice of Chemotherapy in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

420

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Dec 2029

Study completion Jan 2030

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Nov 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this interventional study is to compare the effectiveness and safety of QLS5132 monotherapy with investigator's choice of chemotherapy in participants with platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

Conditions

  • Epithelial Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer

Interventions

  • QLS5132Drug

    Intravenous infusion, Q3W (Day 1 of each 21-day cycle)

  • Liposomal DoxorubicinDrug

    Intravenous infusion, Q4W (Day 1 of each 28-day cycle)

  • PaclitaxelDrug

    Intravenous infusion, Q4W (Days 1, 8, 15, and 22 of each 28-day cycle)

  • TopotecanDrug

    Intravenous infusion, Q4W (Days 1, 8, and 15 of each 28-day cycle)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) Assessed by BICRTime frame: From randomization to the first documented disease progression as assessed by blinded independent central review (BICR) using RECIST v1.1, or death from any cause, whichever occurs first, assessed up to approximately 3 years.
  2. Overall Survival (OS)Time frame: From randomization until death from any cause, assessed up to approximately 3 years.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.